Arca
Skip to content
Tools
Tools

Hot flashes

Drug research and approvals for hot flashes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 33 studies of hot flashes are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 33
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 33 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

2 approved, 13 in phase 3, 8 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Fezolinetant, Veralipride

Gabapentin
Phase 3 Voltage-gated calcium channel modulator
Elinzanetant
Phase 3 Neurokinin 1 receptor antagonist
Medroxyprogesterone acetate
Phase 3 Progesterone receptor agonist
Paroxetine
Phase 3 Serotonin transporter inhibitor
Venlafaxine
Phase 3 Serotonin transporter inhibitor
Estrogens, conjugated
Phase 3 Estrogen receptor agonist
Citalopram
Phase 3 Serotonin transporter inhibitor
Desvenlafaxine
Phase 3 Serotonin transporter inhibitor
Tamoxifen
Phase 3 Estrogen receptor alpha modulator
Filgrastim
Phase 3 Granulocyte colony stimulating factor receptor agonist
Megestrol acetate
Phase 3 Progesterone receptor agonist
Cefepime
Phase 3 Bacterial penicillin-binding protein inhibitor
Levofloxacin anhydrous
Phase 3 DNA gyrase inhibitor
Elacestrant
Phase 2 Estrogen receptor alpha degrader
MF101
Phase 2 Estrogen receptor beta agonist
Nitroglycerin
Phase 2 Soluble guanylate cyclase activator
Prasterone
Phase 2 Unknown
Elismetrep
Phase 2 Transient receptor potential cation channel subfamily M member 8 inhibitor
Methionine
Phase 2
Toluene
Phase 2
PD-0299685
Phase 2
Melatonin
Phase 1 Melatonin receptor agonist
Norleucine
Phase 1
Estetrol anhydrous
Phase 1 Estrogen receptor agonist
Bupivacaine
Early phase 1 Sodium channel protein type IV alpha subunit blocker

How Its Trials Ended

246 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 88 whose ending is known, 57% met their primary endpoint, 13% missed it and 31% stopped early.

  • Completed, result not reported10442%
  • Met its primary endpoint5020%
  • Ongoing3313%
  • Status unknown219%
  • Missed its primary endpoint114%
  • Stopped: enrollment or feasibility114%
  • Stopped: other or unclear114%
  • Stopped: safety21%
  • Stopped: sponsor or business decision21%
  • Stopped: lack of efficacy10%

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 17, 2025LynkuetElinzanetantBayer AGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.